World Wires · story 122091 · corroborated · 1 source(s)

Molecular Mechanisms of Quizartinib Resistance in FLT3 Mutants

Quizartinib, a type II FLT3 inhibitor approved for FLT3-ITD-positive acute myeloid leukemia (AML), is frequently limited by acquired resistance, which aris

Open in the desk

Coverage

What this site indexes